MedTrace Logo

Scopolamine Challenge Study

NCT01213355 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-11-14

No results posted yet for this study

Summary

It is hypothesized that PF-05212377 (SAM-760) will reverse scopolamine induced cognitive impairments in healthy adults subjects.

Conditions

  • Healthy

Interventions

DRUG

Placebo

Capsule, single dose, oral, 1 day

DRUG

Scopolamine

injectable subcutaneous formulation, single dose, 1 day

DRUG

PF-05212377

5 mg, PF-05212377, capsule, single dose, 1 day

DRUG

Scopolamine

injectable subcutaneous formulation, single dose, 1 day

DRUG

PF-05212377

20 mg, capsule PF-05212377, single dose, 1 day

DRUG

scopolamine

injectable subcutaneous formulation, single dose, 1 day

DRUG

PF-05212377

60 mg PF-05212377, capsule, single dose, 1 day

DRUG

scopolamine

injectable sub cutaneous formulation, single dose, 1 day

DRUG

Donepezil

Tablet, 10mg, single dose, 1 day

DRUG

Scopolamine

injectable sub cutaneous formulation, single dose, 1 day

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213355 on ClinicalTrials.gov